Date | Price Target | Rating | Analyst |
---|---|---|---|
1/30/2023 | $7.00 → $10.00 | Underweight → Neutral | JP Morgan |
1/3/2023 | $32.00 → $31.00 | Buy | Needham |
11/4/2021 | $20.00 → $19.00 | Neutral → Underweight | JP Morgan |
11/4/2021 | $78.00 → $71.00 | Buy | HC Wainwright & Co. |
11/4/2021 | $41.00 → $24.00 | Outperform | Raymond James |
10/15/2021 | $51.00 | Buy | BTIG Research |
9/30/2021 | $24.00 → $20.00 | Overweight → Neutral | JP Morgan |
9/1/2021 | $57.00 → $56.00 | Buy | Roth Capital |
HC Wainwright & Co. analyst Edward White maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $9 to $3.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. JP Morgan cut the price target for Sea Limited (NYSE:SE) from $84 to $78. JP Morgan analyst Ranjan Sharma downgraded the stock from Overweight to Neutral. Sea shares gained 0.6% to close at $75.89 on Monday. See how other analysts view this stock. Morgan Stanley raised the price target for Birkenstock Holding plc (NYSE:BIRK) from $44 to $58. Morgan Stanley analyst Edouard Aubin maintained an Equal-Weight rating. Birkenstock shares fell 2.8% to close at $59.78 on Monday. See how other analysts view
Needham analyst Gil Blum maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $12 to $6.
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, July 1, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 100
- PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population - - The Company Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market - - G1 is Sufficiently Funded to Achieve Anticipated Company Profitability in the Second Half of 2025 - - Management to Host Webcast and Conference Call Today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced topline results from the final OS analysis of its Phase 3 PRESERVE 2 trial evaluating the efficacy and safety of
RESEARCH TRIANGLE PARK, N.C., June 05, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 4,650 shares of G1's common stock and 2,400 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the "Amended and Restated 2021 Plan"). These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4). The Amended and Restated 2021 Plan is used exclusively for the grant of equity awards to individuals who
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient Population Showed an Approximately Six-Month Improvement in Median OS Among Patients Receiving Trilaciclib in Combination with the ADC Compared to Historical ADC Data - - Prolonged OS Observed in Patients Receiving Trilaciclib with Prior Anti-PD-(L)1 Therapy and No Prior Oral CDK4/6 Inhibitor - - On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with the TROP2 ADC Includ
SC 13D/A - G1 Therapeutics, Inc. (0001560241) (Subject)
SC 13G/A - G1 Therapeutics, Inc. (0001560241) (Subject)
SC 13G/A - G1 Therapeutics, Inc. (0001560241) (Subject)
SC 13G/A - G1 Therapeutics, Inc. (0001560241) (Subject)
8-K - G1 Therapeutics, Inc. (0001560241) (Filer)
8-K - G1 Therapeutics, Inc. (0001560241) (Filer)
10-Q - G1 Therapeutics, Inc. (0001560241) (Filer)
8-K - G1 Therapeutics, Inc. (0001560241) (Filer)
4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
4 - G1 Therapeutics, Inc. (0001560241) (Issuer)
RESEARCH TRIANGLE PARK, N.C., May 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Monica Thomas as its General Counsel and Chief Compliance Officer. Mrs. Thomas replaces Stillman Hanson who departed the Company in May 2023. "G1 is in the midst of an important period in our evolution, as we evolve our commercial and clinical capabilities to maximize the future value of COSELA® (trilaciclib) and ensure that all appropriate patients may have access to this important drug," said Jack Bailey, Chief Executive Officer of G1 Therapeutics. "As we do so, it is essential that we maintain our fundamental focus o
RESEARCH TRIANGLE PARK, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Norman E. "Ned" Sharpless, M.D., to its Board of Directors. For nearly 30 years, Dr. Sharpless has been committed to the fight against cancer, including serving as one of the scientific founders of G1 in 2008. He is an accomplished oncologist and seasoned public servant who has treated cancer patients, investigated the biologic basis of cancer, and has led academic institutions and government agencies, including most recently serving as Director of the National Cancer Institute (NCI) at the National Institutes of Health
RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors. For more than 30 years, Mr. Lee has developed extensive experience in manufacturing and supply chain management in the life sciences industry. Mr. Lee currently serves as Senior Vice President – Manufacturing & Supply of Merck & Co., Inc., a global premier research-intensive biopharmaceutical health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. "G1's Board of Directors comprises ex
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
JP Morgan upgraded G1 Therapeutics from Underweight to Neutral and set a new price target of $10.00 from $7.00 previously
Needham reiterated coverage of G1 Therapeutics with a rating of Buy and set a new price target of $31.00 from $32.00 previously
JP Morgan downgraded G1 Therapeutics from Neutral to Underweight and set a new price target of $19.00 from $20.00 previously
HC Wainwright & Co. reiterated coverage of G1 Therapeutics with a rating of Buy and set a new price target of $71.00 from $78.00 previously
- PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population - - The Company Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market - - G1 is Sufficiently Funded to Achieve Anticipated Company Profitability in the Second Half of 2025 - - Management to Host Webcast and Conference Call Today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced topline results from the final OS analysis of its Phase 3 PRESERVE 2 trial evaluating the efficacy and safety of
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) Will Be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - - Announced That Final Analysis of Phase 3 PRESERVE 2 Trial Evaluating Overall Survival in 1L Metastatic Triple Negative Breast Cancer (mTNBC) Is Expected to Occur in Late Second Quarter of 2024 - - Cash Runway Expected to Extend into the Third Quarter of 2025 - - Management to Host Webcast and Co
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m. ET. To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the company's website: www.g1therapeutics.com. The webcast will be ar
- Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Net COSELA Revenue Grew 29% in the Fourth Quarter of 2023 to $13.9 Million - - Announced That Final Analysis of Phase 3 PRESERVE 2 Trial Evaluating Overall Survival in Metastatic Triple Negative Breast Cancer is Estimated to Occur in the Third Quarter of 2024 - - Presented New Analyses Indicating that Patients Who Previously Received Trilaciclib in a Clinical Trial Setting Experienced Improved Overall Survival with Subsequent Anticancer Therapies - - Provided Initial Results f
Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB DIHYDROCHLORIDE has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity
Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity
For Immediate Release: February 12, 2021 Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer. Cosela may help protect bone marrow cells from damage caused by chemotherapy by inhi